Japan creates the first effective treatment against the Coronavirus Covid-19, called Favipiravir

China has completed clinical trials of Favipiravir, an antiviral drug that has shown clinical efficacy against the disease caused by the new coronavirus, COVID-19, an official quoted by Agerpres-quoted Xinhua agency said on Tuesday.

Favipiravir, an influenza drug approved for clinical use in Japan in 2014, did not show any obvious side effects in the clinical trial, Zhang Xinmin, director of the National Center for Biotechnological Development, under the authority of the Ministry of Science, said in a press conference. Chinese technology.

Over 80 patients participated in a clinical trial in a hospital in Shenzhen city, located in Guangdong province in southern China. 35 of these patients received treatment with Favipiravir, and 45 were included in a control group.

The results showed that patients receiving Favipiravir treatment had negative results in testing for this virus in a shorter time compared to patients in the control group.

A randomized, multicenter clinical trial conducted by Wuhan University Zhongnan Hospital also suggested that the therapeutic effect of Favipiravir is much better than that seen in the control group.

Favipiravir has been recommended to physician teams and should be included in the COVID-19 diagnostic and treatment plan as soon as possible, Zhang said.

A Chinese pharmaceutical company has received approval from the National Administration for Medical Products to mass-produce the drug and ensure a stable supply, said Zhang, quoted by Xinhua.


Favipiravir, an influenza drug approved for clinical use in Japan in 2014, did not show any adverse reactions during the tests, said Zhang Xinmin, director of the National Center for Biotechnological Development, under the authority of the Chinese Ministry of Science and Technology.

Over 80 patients participated in a clinical trial in a hospital in Shenzhen City. 35 of them received treatment with Favipiravir, and 45 were included in a control group. The results showed that patients receiving Favipiravir had negative results for testing for this virus in a shorter time compared to patients in the control group.

A clinical study conducted by Wuhan University Zhongnan Hospital also suggested that the therapeutic effect of Favipiravir is much better than that seen in the control group.

Leave a Reply

Your email address will not be published. Required fields are marked *